drugset / Trial / NCT04025372
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Phase 2
Active not recruiting
234 enrolled
Brigham and Women's Hospital
Bayer · collabDecipher Biosciences · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This research study is comparing the use of a new form of hormonal therapy used with radiation as a possible treatment for intermediate risk prostate cancer. More specifically, this research would help determine whether this new form of hormonal therapy is as effective as the standard hormone therapy while also preserving erectile function.
Timeline
- Start
- 2020-06-01
- Primary completion
- 2027-10-01
- Completion
- 2028-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bicalutamide | Other / unclassified | — | Oral |
| Subject | Darolutamide | Other / unclassified | — | Oral |